Description

Docetaxel (Docetaxel) Concentrate for Solution for Infusions 10 mg/ml. 2 ml. (20 mg.) Vial №1

Ingredients:

Each vial contains 20 mg of Docetaxel in a 2 ml concentrate for solution for infusions.

Dosage:

The dosage of Docetaxel is determined by the prescribing healthcare provider based on the patient’s condition, weight, and other factors. It is administered intravenously over a specific period as directed.

Indications:

Docetaxel is indicated for the treatment of various types of cancers, including breast cancer, lung cancer, prostate cancer, and others. It works by interfering with the growth and spread of cancer cells in the body.

Contraindications:

Do not use Docetaxel if you have a history of severe allergic reactions to docetaxel or other drugs formulated with polysorbate 80. It is important to inform your healthcare provider about any allergies or medical conditions before starting treatment.

Directions:

Administered by a healthcare professional in a clinical setting, Docetaxel is given through a vein over a specific time frame. It is crucial to follow the instructions provided by the healthcare team to ensure the safe and effective use of this medication.

Scientific Evidence:

Studies have shown the efficacy of Docetaxel in improving survival rates and reducing tumor size in various types of cancers. Research published in the Journal of Clinical Oncology demonstrated the benefits of Docetaxel-based chemotherapy in advanced breast cancer patients.

Additional Information:

Docetaxel may cause side effects such as hair loss, nausea, fatigue, and low blood cell counts. Regular monitoring and supportive care are essential during treatment to manage any adverse reactions effectively.

Docetaxel, a member of the taxane family, exerts its pharmacological effects by disrupting microtubule function, leading to cell cycle arrest and ultimately cell death. This mechanism makes it a valuable component in cancer treatment regimens, especially in cases where other therapies have been ineffective.

Clinical trials have demonstrated the comparative effectiveness of Docetaxel against other chemotherapy agents in terms of response rates and overall survival in various cancer types. Its role in combination therapies and as a single agent has been well-established through extensive research and real-world clinical experience.